Yichen Zhang

1.1k total citations · 1 hit paper
51 papers, 668 citations indexed

About

Yichen Zhang is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Yichen Zhang has authored 51 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 15 papers in Economics and Econometrics and 10 papers in Oncology. Recurrent topics in Yichen Zhang's work include Lung Cancer Treatments and Mutations (15 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Economic and Financial Impacts of Cancer (9 papers). Yichen Zhang is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Economic and Financial Impacts of Cancer (9 papers). Yichen Zhang collaborates with scholars based in China, United States and United Kingdom. Yichen Zhang's co-authors include Xiaodong Guan, Lizheng Shi, Yi‐Long Wu, Qing Zhou, Anita K. Wagner, Luwen Shi, Hui Shao, Xu‐Chao Zhang, Hai‐Yan Tu and Jian Su and has published in prestigious journals such as Nature Communications, Scientific Reports and The Lancet Oncology.

In The Last Decade

Yichen Zhang

47 papers receiving 662 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhalable biohybrid microrobots: a non-invasive approach for lung treatment

2025 16 citations Zhengxing Li, Zhongyuan Guo et al. Nature Communications profile →

Peers

Countries citing papers authored by Yichen Zhang

Since Specialization

Citations

This map shows the geographic impact of Yichen Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yichen Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yichen Zhang more than expected).

Fields of papers citing papers by Yichen Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yichen Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yichen Zhang. The network helps show where Yichen Zhang may publish in the future.

Co-authorship network of co-authors of Yichen Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Yichen Zhang. A scholar is included among the top collaborators of Yichen Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yichen Zhang. Yichen Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhalable biohybrid microrobots: a non-invasive approach for lung treatment breakdown → 2025 ·Nature Communications ·Zhengxing Li, Zhongyuan Guo, Fangyu Zhang, Lei Sun, Hao Luan, (unknown), (unknown), Yichen Zhang, Christine Tang, Andrew X. Zhu, Yiyan Yu, Shichao Ding, Dan Wang, An‐Yi Chang, Lu Yin, Lynn M. Russell, Weiwei Gao, Ronnie H. Fang, Liangfang Zhang, Joseph Wang	16
2	Picoeukaryote-based biohybrid microrobots for active delivery in the kidney 2025 ·Science Advances ·Zhengxing Li, Dan Wang, Hao Luan, An‐Yi Chang, (unknown), Lei Sun, (unknown), Wei‐Ting Shen, Yiyan Yu, (unknown), Shichao Ding, (unknown), Yichen Zhang, Yifei Peng, Ronnie H. Fang, Weiwei Gao, Liangfang Zhang, Joseph Wang	0
3	Online estimation and inference for robust policy evaluation in reinforcement learning 2025 ·The Annals of Statistics ·Weidong Liu, Jiyuan Tu, Xi Chen, Yichen Zhang	0
4	Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis 2025 ·The Lancet Oncology ·Yichen Zhang, (unknown), (unknown), Luwen Shi, Huseyin Naci, Anita K. Wagner, Joseph S. Ross, Xiaodong Guan	2
5	Biodegradable zwitterionic polymer-cloaked defective metal–organic frameworks for ferroptosis-inducing cancer therapy 2024 ·International Journal of Pharmaceutics ·Minghua Zhang, Xianxian Yao, Jianbin Xu, Jiaying Song, (unknown), (unknown), Yichen Zhang, Liangliang Zhu, Wuli Yang	5
6	Potential effects of sialic acid and 3′-Sialyllactose on intestinal health and anti-cardiovascular disease in mice fed with a high-fat diet 2024 ·Journal of Functional Foods ·(unknown), Wei Zhang, (unknown), (unknown), Yichen Zhang, (unknown), (unknown)	4
7	Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005–2019 2024 ·Primary care diabetes ·(unknown), Dawei Guan, (unknown), Yichen Zhang, Hans K. Ghayee, (unknown), Hui Shao	1
8	Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis 2024 ·EClinicalMedicine ·(unknown), (unknown), Yi Zhang, Lan Zhang, (unknown), Yichen Zhang, Luwen Shi, Wei Liu, Zhuoling An, Xiaodong Guan	12
9	Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020 2024 ·The Lancet Regional Health - Western Pacific ·(unknown), Yichen Zhang, Ziyue Xu, Guoan Wang, Yue Zhou, (unknown), Luwen Shi, Huseyin Naci, Anita K. Wagner, Xiaodong Guan	7
10	Incremental burden on health‐related quality of life, health service utilization and direct medical expenditures associated with cognitive impairment among non‐institutionalized people with diabetes aged 65 years and older 2023 ·Diabetes Obesity and Metabolism ·(unknown), (unknown), (unknown), Yichen Zhang, Ping Zhang, Shichao Tang, Joshua D. Brown, Jingchuan Guo, Yongkang Zhang, Hui Shao	3
11	The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data 2023 ·Journal of Global Health ·(unknown), Yichen Zhang, Anita K. Wagner, (unknown), Luwen Shi, Xiaodong Guan	11
12	An analysis of the current situation of China's model of combining medical care with nursing care under the background of the internet plus 2023 ·Minerva Medica ·(unknown), Yichen Zhang, (unknown), Lijun Wu, (unknown), (unknown), Xuanxuan Wang	3
13	Patient and clinician nudges to improve symptom management in advanced cancer using patient-generated health data: study protocol for the PROStep randomised controlled trial 2022 ·BMJ Open ·Ravi B. Parikh, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Peter Gabriel, Yichen Zhang, Lynn M. Schuchter, Lawrence N. Shulman, Jinbo Chen, Mitesh S. Patel, Christopher R. Manz	5
14	Efficacy and safety of 3D printing-assisted percutaneous nephrolithotomy in complex renal calculi 2022 ·Scientific Reports ·(unknown), (unknown), (unknown), (unknown), Yichen Zhang, Zekai Zhang, Yuntao Chen, (unknown), Bo Zhang	14
15	EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib 2018 ·Journal of Thoracic Oncology ·Qi Zhang, Xu‐Chao Zhang, Jin‐Ji Yang, Zhenfan Yang, Yu Bai, Jian Su, Zheng Wang, Zhou Zhang, Yang Shao, Qing Zhou, Jin‐Hyoung Kang, E‐E Ke, Yichen Zhang, Zhong‐Yi Dong, Zhihong Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu	56
16	A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology 2017 ·Translational Cancer Research ·Hai‐Yan Tu, Yichen Zhang, Yi‐Long Wu	1
17	Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review 2017 ·PharmacoEconomics ·(unknown), Yichen Zhang, Hui Shao, Lizheng Shi	58
18	P3.02b-095 Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs 2017 ·Journal of Thoracic Oncology ·Yichen Zhang, (unknown), E‐E Ke, Zhihong Chen, Jian Su, Zhong‐Yi Dong, Chong‐Rui Xu, Hai‐Yan Tu, Hong‐Hong Yan, Wen‐Zhao Zhong, Jin Yang, Xu‐Chao Zhang, Yi‐Long Wu, Qing Zhou	0
19	Isolation and screeing of digestive enzyme producing probiotics from intestine of Litopenaeus vannamei. 2016 ·JOURNAL OF FISHERIES OF CHINA ·(unknown), (unknown), Yichen Liu, Yichen Zhang, (unknown), (unknown)	5
20	Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial 2015 ·Critical Care ·Bei Hu, Heng Ye, Cheng Sun, Yichen Zhang, (unknown), Fanghong Wu, Zhaohui Liu, (unknown), (unknown), (unknown), Hao Wu, (unknown), Junling Liu, (unknown), Weiying Chen, Zhiqiang Nie, Zaiyi Liu, Chunbo Chen	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact